Protocols of dual diagnosis intervention in schizophrenia

Addictive Disorders and their Treatment

Volumn 10, Issue 3, 2011, Pages 131-154

  Roncero, Carlos ^a,b,c   Barral, Carmen ^a,c   Grau Lopez, Lara ^a,c   Bachiller, Diana ^a,c   Szerman, Néstor ^c,d   Casas, Miguel ^a,b,c   Ruiz, Pedro ^e  

^a CAS (Outpatient Drug Clinic) Vall d'Hebron   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c External Quality Asessment   (Spain)

^d HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

alcohol; cannabis; cocaine; dual diagnosis; dual disorder; heroin; pharmacotherapy; schizophrenia; substance use disorder; treatment

Indexed keywords

ACAMPROSATE; ALCOHOL; AMISULPRIDE; AMPHETAMINE; BENZODIAZEPINE; CAFFEINE; CANNABIS; CLOZAPINE; COCAINE; DECANOIC ACID; DISULFIRAM; DULOXETINE; FLUPENTIXOL; HALOPERIDOL; METHADONE; METHAMPHETAMINE; MIRTAZAPINE; NALTREXONE; NEUROLEPTIC AGENT; NICOTINE; OLANZAPINE; OPIATE AGONIST; OPIATE ANTAGONIST; PERPHENAZINE; RISPERIDONE; THEOPHYLLINE; TIAPRIDE; UNINDEXED DRUG; VENLAFAXINE; ZUCLOPENTHIXOL;

ALCOHOL CONSUMPTION; ANXIETY; AVERSION THERAPY; CLINICAL FEATURE; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; HALLUCINATION; HEALTH CARE FACILITY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDLINE; MENTAL DISEASE; OPIATE ADDICTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOPHARMACOLOGY; PSYCHOSIS; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA; SOCIAL BEHAVIOR; SUBSTANCE ABUSE; VIOLENCE;

EID: 80052228531     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/ADT.0b013e318227ecdc     Document Type: Review

References (185)

1. Khantzian E. The self-medication hypothesis of addictive disorders: Focus on heroin and cocaine. Harv Rev Psychiatry. 1985;142:1259.
2. Green A, Brown E. Comorbid schizophrenia and substance abuse. J Clin Psychiatry. 2006;67:e08.
3. Regier D, Farmer M, Rae D, et al. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA. 1990;264:2511-2518.
4. Swartz M, Wagner H, Swanson J, et al. Substance use in persons with schizophrenia: Baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis. 2006;194:164-172.
5. SEPD (Sociedad Espanola de Patología Dual). [Epidemiological study to determine the prevalencia, diagnosis and therapeutic attitude of the dual pathology in the community of Madrid 2008]. Available in: Http://www. patologiadual.es/docs/estudio-epidemiologico-PD-CE2008-NOV08.pdf. Accessed: November 1, 2010
6. Mueser K, Drake R, Wallach M. Dual diagnosis: A review of etiological theories. Addict Behav. 1998; 23:717-734. (Pubitemid 28443188)
7. Dixon L, Haas G, Weiden P, et al. Acute effects of drug abuse in schizophrenic patients: Clinical observations and patients' self-reports. Schizophr Bull. 1990;16:69-79. (Pubitemid 20110376)
8. Grau-López L, Barral C, Roncero C, et al April 2009;Psychosis and abuse of substances in an ambulatory program of dual pathology. Present in: International College of Neuro-Psychopharamacology (CINP). International Thematic Meeting Edinburgh. Major psychoses and substance abuse. Edinburgh, Scotland.
9. Scheller-Gilkey G, Woolwine B, Cooper I, et al. Relationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics. Am J Drug Alcohol Abuse. 2003;29:553-566. (Pubitemid 37093366)
10. Potvin S, Joyal CC, Pelletier J, et al. Contradictory cognitive capacities among substance-abusing patients with schizophrenia: A meta-analysis. Schizophr Res. 2008;100:242-251. (Pubitemid 351318147)
11. Negrete J. Clinical aspects of substance abuse in persons with schizophrenia. Can J Psychiatry. 2003;48:14-21. (Pubitemid 36331415)
12. Green A. Schizophrenia and comorbid substance use disorder: Effects of antipsychotics. J Clin Psychiatry. 2005;66:(Suppl 6):21-26. (Pubitemid 41243258)
13. Hall W. The psychotogenic effects of cannabis use: Challenges in reducing residual uncertainties and communicating the risks. Addiction. 2004;99: 511-512.
14. Veen N, Selten J, Tweel Van der, et al. Cannabis use and age onset of schizophrenia. Am J Psychiatry. 2004;161:501-506. (Pubitemid 38326105)
15. Batel P. Addition and schizophrenia. Eur Psychiatry. 2000;15:115-122.
16. Lambert M, Conus P, Lubman D, et al. The impact of substance use disorders on clinical outcome in substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scan. 2005;112:141-148. (Pubitemid 41003193)
17. Schuckit M, Anthenelli M, Bucholz K, et al. The time course of development of alcohol related problems in men and women. J Study Alcohol. 1995;56: 218-225.
18. Abel K, Drake R, Goldstein J. Sex differences in schizophrenia. Int Rev Psychiatry. 2010;22: 417-428.
19. Gearon J, Bellack A. Sex differences in illness presentation, course and level of functioning in substance- abusing schizophrenia patients. Schizophr Res. 2000;43:65-70. (Pubitemid 30316318)
20. Hawton K, Sutton L, Haw C, et al. Schizophrenia and suicide: Systematic review of risk factors. Br J Psychiatry. 2005;187:9-20. (Pubitemid 41002508)
21. Bailey L, Maxwell S, Brandabur M. Substance abuse as a risk factor for tardie diskinesia: A retrospective analysis of 1027 patients. Psychopharmacol Bull. 1997;3:177-181.
22. Carey M, Weinhardt I, Carey K. Prevalence of infection with HIV among the seriously mentally ill: Review of research and implications for practice. Prof Psychol Res Pract. 1995;26:262-268.
23. Wilkins J. Pharmacotherapy of schizophrenic patients with comorbid substance abuse. Schizophr Bull. 1997;23:215-218.
24. Wilk J, Marcus S, West J, et al. Substance abuse and the management of medication nonadherence in schizophrenia. J Nerv Ment Dis. 2006;194:454-457.
25. Novick D, Haro J, Suárez D, et al. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010;176:109-113.
26. Ascher-Svanum H, Faries D, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67:453-460.
27. LeDuc P, Mittleman G. Schizophrenia and psychostimulant abuse: A review and re-analysis of clinical evidence. Psychopharmacology (Berl). 1995;121: 407-427.
28. Buckley P. Substance abuse in schizophrenia: A review. J Clin Psychiatry. 1998;59:(Suppl 3):26-30. (Pubitemid 28196367)
29. Baigent M, Holme G, Hafner R. Self reports of the interaction between substance abuse and schizophrenia. Aust N Z J Psychiatry. 1995;29:69-74.
30. Van Kammen D, Boronow J. Dextro-amphetamine diminishes negative symptoms in schizophrenia. Int Clin Psychopharmacol. 1988;3:111-115.
31. Carnwath T, Garvey T, Holland M. The prescription of dexamphetamine to patients with schizophrenia and amphetamine dependence. J Psychopharmacol. 2002;16:373-377. (Pubitemid 35470584)
32. Roncero C, Ramos J, Collazos F, et al. [Psycotic complications in cocaine users]. Adicciones. 2001; 13:(Suppl 2):179-189. (Pubitemid 34007756)
33. Laudet A, Mogura S, Vogel H, et al. Recovery challenges among dually diagnosed individuals. J Subst Abuse Treat. 2000;18:321-329. (Pubitemid 30254354)
34. Van Harten P, Van Trier J, Horwitz E, et al. Cocaine as a risk factor for neuroleptic induced acute dystonia. J Clin Psychiatry Mart. 1998;59:128-130. (Pubitemid 28150859)
35. Smelson D, Williams J, Ziedonis D, et al. A doubleblind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients. J Subst Abuse Treat. 2004;27:45-49. (Pubitemid 38829778)
36. North C, Pollio D, Smith E, et al. Correlates of early onset and chronicity of homelessness in large urban homeless population. J Ner Ment Dis. 1998;186: 393-400. (Pubitemid 28363354)
37. Nolte S, Wong D, Lachford G. Amphetamines for schizophrenia. Cochrane Database Syst Rev. 2004; 18:CD004964.
38. Jacobs E, Fujii D, Schiffman J, et al. An exploratory analysis of neurocognition in methamphetamineinduced psychotic disorder and paranoid schizophrenia. Cogn Behav Neurol. 2008;21:98-103.
39. Featherstone R, Kapur S, Fletcher P. The amphetamine- induced sensitized state as a model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1556-1571. (Pubitemid 47625703)
40. Galazyn M, SteinbergM, Gandhi K, et al. Reasons for smoking among individuals with schizophrenia. Schizophr Res. 2010;122:268-269.
41. Baker A, Richmond R, Haile M, et al. Characteristics of smokers with a psychotic disorder and implications for smoking interventions. Psychiatry Res. 2007;150:141-152. (Pubitemid 46386295)
42. De Leon J. Smoking and vulnerability for schizophrenia. Schizophr Bull. 1996;22:405-409. (Pubitemid 26295343)
43. George T, Vessicchio J, Termine A, et al. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology. 2002;26:75-85. (Pubitemid 34075278)
44. Smith R, Singh A, Infante M, et al. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology. 2002;27:479-497. (Pubitemid 35253795)
45. Mobascher A, Winterer G. The molecular and cellular neurobiology of nicotine abuse in schizophrenia. Pharmacopsychiatry. 2008;41:(Suppl 1): S51-S59.
46. Barnes M, Lawford B, Burton S, et al. Smoking and schizophrenia: Is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use? Aust N Z J Psychiatry. 2006;40:575-580. (Pubitemid 43805628)
47. Goff D, Henderson D, Amico E. Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. Am J Psychiatry. 1992; 149:1189-1194.
48. Ziedonis D. Nicotine dependence and schizophrenia. Hosp Community Psychiatry. 1994;45: 204-206. (Pubitemid 24079650)
49. Gurpegui M, Aguilar M, Martínez-Ortega J, et al. Caffeine intake in outpatients with schizophrenia. Schizophr Bull. 2004;30:935-945. (Pubitemid 40469527)
50. Gurpegui M, Aguilar M, Martínez-Ortega J, et al. Fewer but heavier caffeine consumers in schizophrenia: A case-control study. Schizophr Res. 2006; 86:276-283. (Pubitemid 44234043)
51. Williams J, Gandhi K. Use of caffeine and nicotine in people with schizophrenia. Curr Drug Abuse Rev. 2008;1:155-161.
52. Koskinen J, Löhönen J, KoponenH, et al. Prevalence of alcohol use disorders in schizophrenia -a systematic review and meta-analysis. Acta Psychiatr Scand. 2009;120:85-96.
53. Addington J, Duchak V. Reasons for substance use in schizophrenia. Acta Psychiatr Scand. 1997;96: 329-333. (Pubitemid 27496012)
54. Bowie C, Serper M, Riggio S, et al. Neurocognition, symptomatology, and functional skills in older alcohol- abusing schizophrenia patients. Schizophr Bull. 2005;31:175-182. (Pubitemid 41214366)
55. Pencer A, Addington J. Substance use and cognition in early psychosis. J Psychiatry Neurosci. 2003;28: 48-54. (Pubitemid 36315351)
56. Carey K, Carey M, Simons J. Correlates of substance use disorder among psychiatric outpatients: Focus on cognition, social role functioning, and psychiatric status. J Nerv Ment Dis. 2003;191:300-308. (Pubitemid 36627204)
57. Heila H, Isometsa E, Henriksson M, et al. Suicide and schizophrenia: A nationwide of 92 suicide victims with schizophrenia. Am J Psychiatry. 1997; 154:1235-1242.
58. National Institute of Alcohol Abuse and Alcoholism (NIAAA). Harmful interactions: Mixing Alcohol with Medicines. 2010. Available http://www.niaaa. nih.gov/Publications/PamphletsBrochuresPosters/ English/Documents/Harmful- Interactions.pdf. Accessed November 1, 2010.
59. McCreadie R. Use of drugs, alcohol and tobacco by people with schizophrenia: Case-control study. Br J Psychiatry. 2002;181:321-325. (Pubitemid 35178564)
60. Kawohl W, Rössler W. Cannabis and schizophrenia: New findings in an old debate. Neuropsychiatr. 2008;22:223-229.
61. Roncero C, Collazos F, Valero S, et al. Cannabis consumption and development of psicosis: State of the art. Actas Esp Psiquiatr. 2007;35:182-189.
62. Sevy S, Robinson D, Napolitano B, et al. Are cannabis use disorders associated with an earlier age at onset of psychosis? a study in first episode schizophrenia. Schizophr Res. 2010;120:101-107.
63. Foti D, Kotov R, Guey L, et al. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry. 2010;167: 987-993.
64. Gouzoulis-Mayfrank E. Dual diagnosis psychosis and substance use disorders: Theoretical foundations and treatment. Kinder Jugendpsychiatr Psychother. 2008;36:245-253.
65. Schiffman J, Nakamura B, Earleywine M, et al. Symptoms of schizotypy precede cannabis use. Psychiatry Res. 2005;134:37-42. (Pubitemid 40460971)
66. Hjorthøj C, Fohlmann A, Nordentoft M. Treatment of cannabis use disorders in people with schizophrenia spectrum disorders: A systematic review. Addict Behav. 2009;34:520-525.
67. D'Souza D, Abi-Saab W, Madonick S, et al. Delta 9- tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis and addiction. Biol Psychiatry. 2005;57:594-608.
68. Arias F, Padín J, Fernández González M. Drug use and dependence in schizophrenia. Actas Luso Esp Neurol Psiquiatr. 1997;25:379-389.
69. Brizer D, Hartman N, Sweeney J, et al. Effect of methadone plus neuroleptics on treatment resistant chronic paranoid schizophrenia. Am J Psychiatry. 1985;142:1106-1107. (Pubitemid 16216097)
70. Schmauss C, Yassouridis A, Emrich H. Antipsychotic effect of buprenorphine in schizophrenia. Am J Psychiatry. 1987;144:1340-1342.
71. Brunette M, Noordsy D, Xie H, et al. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr Serv. 2003;54:1395-1401. (Pubitemid 37220041)
72. Smith J, Stephen H. Schizophrenia and substance abuse. Br J Psychiatry. 1994;165:13-21. (Pubitemid 24224832)
73. Kranzler H, Kadden R, Babor T, et al. Validity of the SCID in substance abuse patients. Adicction. 1996; 91:859-868. (Pubitemid 26172923)
74. Hasin D, Samet S, Nunes E, et al. Diagnosis of comorbid psychiatric disorders in substance users assessed with the psychiatric research interview for substance and mental disorders for DSM-IV. Am J Psychiatry. 2006;163:689-696. (Pubitemid 44464580)
75. Gregg L, Barrowclough C, Haddock G. Development and validation of a scale for assessing reasons for substance use in schizophrenia: The ReSUS scale. Addict Behav. 2009;34:830-837.
76. Owen R, Fischer E, Booth B, et al. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv. 1996;47: 853-858. (Pubitemid 26264738)
77. Mueser K, Bellack A, Blanchard J. Comorbidity of schizophrenia and substance abuse: Implications for treatment. J Consulting Clinical Psychology. 1992;60:845-856.
78. Lubman D, King J, Castle D. Treating comorbid substance use disorders in schizophrenia. Int Rev Psychiatry. 2010;22:191-201.
79. Akerele E, Levin F. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. Am J Addict. 2007;16:260-268. (Pubitemid 47174581)
80. Sayers S, Campbell E, Kondrich J, et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis. 2005;193:379-386. (Pubitemid 40800627)
81. Van Nimwegen L, De Haan L, Van Beveren N, et al. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: A double-blind randomized controlled trial. Can J Psychiatry. 2008;53:400-405. (Pubitemid 351878642)
82. Rubio G, Martínez I, Ponce G, et al. Long acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry. 2006;51:531-539. (Pubitemid 44166341)
83. Petrakis I, Nich C, Ralevski E. Psychotic spectrum disorders and alcohol abuse: A review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull. 2006;32:644-654. (Pubitemid 44412852)
84. Petrakis I, Poling J, Levinson C, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry. 2005;57:1128-1137. (Pubitemid 40615774)
85. Tsoi D, Porwal M, Webster A. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2010;16:6CD007253.
86. 2010;16:6CD007253 86. National Institute for Clinical Excellence (NICE). Guidelines Development methods. Guideline Development Methods. Chapter 7: Reviewing and grading the evidence [Internet]. London: NICE; 2008. Available in: Http://www.nice.org.uk/guidelinesmanual. Accessed: November 1, 2010.
87. San L, Arranz B, Martínez-Raga J. Antipsychotic drug treatment of schizophrenic patients with substance abuse disorders. Eur Addict Res. 2007;13:230-243. (Pubitemid 47414341)
88. McEvoy J, Freudenreich O, Levin E, et al. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology. 1995;119:124-126.
89. Shaw G, Waller S, Majumdar S, et al. Tiapride in the prevention of relapse in recently detoxified alcoholics. Br J Psychiatry. 1994;165:515-523. (Pubitemid 24305962)
90. Bowers M, Mazure C, Nelson J, et al. Psychotogenic drug use and neuroleptic response. Schizophr Bull. 1990;16:81-85. (Pubitemid 20110377)
91. Modell J, Mountz J, Glaser F, et al. Effect of haloperidol on measures of craving and impaired control in alcoholic subjects. Alcohol Clin Exp Res. 1993;17: 234-240. (Pubitemid 23135424)
92. Brunette M, Drake R, Xie H, et al. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull. 2006;32:637-643. (Pubitemid 44412851)
93. Albanese M, Khantzian E, Murphy S. Decreased substance use in chronically psychotic patients treatment with clozapine. Am J Psychiatry. 1994; 151:780-781. (Pubitemid 24140576)
94. Marcus R, Snyder R. Reduction of comorbid substance abuse with clozpine. Am J Psychiatry. 1995;152:959.
95. Tsuang J, Eckman T, Shaner A, et al. Clozapina for substance-abusing schizophrenic patients. Am J Psychiatry. 1999;157:1119-1120.
96. Sand P, Soyka M. Substance abuse in clozapinetreated schizophrenic patients. J Neuropsychiatry Clin Neurosci. 1997;9:626-627. (Pubitemid 28029763)
97. Lee M, Dickson R, Campbell M, et al. Clozapine and substance abuse in patients with schizophrenia. Can J Psychiatry. 1998;43:855-856. (Pubitemid 28518678)
98. Volavka J. The effects of clozapine on aggression and substance abuse in schizophrenic patients. J Clin Psychiatry. 1999;60:(Suppl 12):43-46. (Pubitemid 29283183)
99. Drake R, Xie H, McHugo G, et al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000; 26:441-449. (Pubitemid 30423220)
100. Zimmet S, Strous R, Burgess E, et al. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: A retrospective survey. J Clin Psychopharmacol. 2000;20: 94-98. (Pubitemid 30056360)
101. Kelly D, Gale E, Conley R. Clozapine treatment in patients with prior substance abuse. Can J Psychiatry. 2003;48:111-114. (Pubitemid 36402212)
102. Green A, Burgess E, Dawson R, et al. Alcohol and cannabis use in schizophrenia: Effects of clozapine versus risperidone. Schizophr Res. 2003;60:81-85. (Pubitemid 36015790)
103. Kim J, Kim D, Marder S. Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:984-988. (Pubitemid 351609233)
104. Conley R, Kelly D, Gale E. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr Res. 1998;33: 95-101. (Pubitemid 28439250)
105. Littrell K, Petty R, Hilligoss N, et al. Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat. 2001;21: 217-221. (Pubitemid 34041006)
106. Tsuang J, Marder S, Han A, et al. Olanzapine treatment for patients with schizophrenia and cocaine abuse. J Clin Psychiatry. 2002;93: 1180-1181. (Pubitemid 36084066)
107. Green A, Tohen M, Hamer R, et alHGDH Research Group. First episode schizophrenia-related psychosis and substance use disorders: Acute response to olanzapine and haloperidol. Schizophr Res. 2004; 66:125-135. (Pubitemid 38041110)
108. Smelson D, Ziedonis D,Williams J, et al. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: A preliminary report. J Clin Psychopharmacol. 2006;26:9-12. (Pubitemid 43167083)
109. Gerra G, Di Petta G, D'Amore A, et al. Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders. Clin Neuropharmacol. 2007;30:127-135. (Pubitemid 46871862)
110. Huang C. Risperdal reduces alcohol use in dual disabled schizophrenia patients. Eur Neuropsychopharmacol. 1996;6:43.
111. Gupta N, Basu D. Does risperidone reduce concomitant substance abuse in cases of schizophrenia? Can J Psychiatry. 2001;46:862-863. (Pubitemid 34062469)
112. Casas M, Gutiérrez M, Gibert J, et al. Risperidone in the treatment of psychotic patients with opiate abuse and dependence. Actas Esp Psiquiatr. 2001; 29:380-385. (Pubitemid 33673994)
113. Smelson D, Losonczy M, Kaune M, et al. Risperidone decreases craving and relapses in withdrawn cocaine- dependent schizophrenics. Schizophr Res. 2002;53:160.
114. Albanese M, Suh J. Risperidone in cocaine-dependent patients with comorbid psychiatric disorders. J Psychiatr Pract. 2006;12:306-311. (Pubitemid 44439987)
115. Brown S, Nejtek V, Perantie B, et al. Cocaine and amphetamine use in patients with psychiatric illness: A randomized trial of typical antipsychotic continuation or discontinuation. J Clin Psychopharmacol. 2003;23:384-388. (Pubitemid 36951181)
116. Weisman R. Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: A case report. Int J Psychiatry Med. 2003;33:85-89. (Pubitemid 36927701)
117. Potvin S, Stip E, Lipp O, et al. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: An open-label trial. Curr Med Res Opin. 2006;22:1277-1285. (Pubitemid 44085579)
118. Stuyt E, Sajbel T, Allen M. Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders. Am J Addict. 2006;15: 166-173.
119. Beresford T, Clapp L, Martin B, et al. Aripiprazole in schizophrenia with cocaine dependence: A pilot study. J Clin Psychopharmacol. 2005;25: 363-366. (Pubitemid 41060257)
120. Brown S, Jeffress J, Liggin J, et al. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry. 2005;66: 756-760. (Pubitemid 40942423)
121. Desseilles M, Mathot F, Desseilles M. Aripiprazole diminishes cannabis use in schizophrenia. J Neuropsychiatry Clin Neurosci. 2008;20:117-118. (Pubitemid 351295049)
122. McRae-Clark A, VerduinM, Tolliver B, et al. An openlabel trial of aripiprazole treatment in dual diagnosis individuals: Safety and efficacy. J Dual Diagnosis. 2009;5:83-96.
123. Dervaux A, Cazali J. Clozapine and amisulpride in refractory schizophrenia and alcohol dependence. J Clin Psychopharmacol. 2007;27:514-516. (Pubitemid 47415054)
124. Schilkrut R, Cabrera J, Morales E, et al. Neuroleptics in the treatment of drug dependence in schizophrenics: A study with flupenthixol decanoate. Psychopharmacology. 1988;96:342.
125. Soyka M, Aichmuller C, Bardeleber U, et al. Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: Results from an open clinical study. Eur Addict Res. 2003;9:65-72. (Pubitemid 36351186)
126. Henningfield J, Shiffman S, Ferguson S, et al. Tobacco dependence and withdrawal: Science base, challenges and opportunities for pharmacotherapy. Pharmacol Ther. 2009;123:1-16.
127. Baker A, Richmond R, Haile M, et al. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. Am J Psychiatry. 2006;163:1934-1942. (Pubitemid 44807785)
128. Mueser K, Noordsy D, Fox L, et al. Disulfiram treatment for alcoholism in severe mental illness. Am J Addict. 2003;12:242-252. (Pubitemid 36950973)
129. Fisher C. Catatonia due to disulfiram toxicity. Arch Neurol. 1989;46:798-804.
130. Petrakis IL, O'Malley S, Rounsaville B, et al. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology. 2004;172:291-297. (Pubitemid 38392322)
131. Batki S, Dimmock J, Wade M, et al. Monitored naltrexone without counselling for alcohol abuse/ dependence in schizophrenia-spectrum disorders. Am J Addict. 2007;16:253-259. (Pubitemid 47174579)
132. Swift R, Pettinati H. Choosing pharmacotherapies for the COMBINE Study process and procedures: An investigational approach to combination pharmacotherapy for the treatment of alcohol dependence. J Stud Alcohol Suppl. 2005;15:141-147. (Pubitemid 41193188)
133. Ávila J, Á lvarez A. Treatment of comorbid disorders in opioid-dependent patients. Monografías Psiquiatri á. 1999;4:41-48.
134. Roncero C, Sáez-Francàs N, Castells X, et al. Efficacy and clinical management of buprenorphine. Trastornos Adictivos. 2008;10:77-87. (Pubitemid 352018909)
135. Gerra G, Leonardi C, D'Amore A, et al. Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30: 265-272. (Pubitemid 43288065)
136. Wobrock T, Soyka M. Pharmacotherapy of patients with schizophrenia and substance abuse. Expert Opin Pharmacother. 2009;10:353-367.
137. Ponce G, Rodríguez-Jiménez R. Use of antiepileptics in Adicctions. Actas Esp Psiquiatr. 2008;36:22-27.
138. Johnson B, Ait-Daoud N, Akhtar F, et al. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: A randomized controlled trial. Arch Intern Med. 2005;165: 1600-1605. (Pubitemid 41124153)
139. Tiihonen J, Halonen P, Wahlbeck K, et al. Topiramate add-on in treatment-resistant schizophrenia: A randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry. 2005;66: 1012-1015. (Pubitemid 41191793)
140. Huguelet P, Morand-Collomb S. Effect of topiramate augmentation on two patients suffering from schizophrenia or bipolar disorder with comorbid alcohol abuse. Pharmacol Res. 2005;52:392-394. (Pubitemid 41534617)
141. Lising-Enriquez K, Blank D, Cushing S, et al. Treatment of co-morbid cocaine dependence in schizophrenia with topiramate. Schizophr Res. 2010; 116:97.
142. Schik G, Wedegaertner F, Liersch J, et al. Oxcarbazepine versus carbamazepine in the treatment of alcohol withdrawal. Addict Biol. 2005;10:283-288. (Pubitemid 41306332)
143. Mueller T, Stout R, Rudden S, et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res. 1997;21:86-92.
144. Kalyoncu A, Mirsal H, Pektas O, et al. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: A potent anti-craving effect? J Psychopharmacol. 2005;19:301-305. (Pubitemid 40694949)
145. Kremer I, Vass A, Gorelik I, et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry. 2004;56:441-446. (Pubitemid 39195324)
146. Brady K, Myrick H, Henderson S, et al. The use of divalproex in alcohol relapse prevention: A pilot study. Drug Alcohol Depend. 2002;67: 323-330. (Pubitemid 34786267)
147. Ziedonis D, Smelson D, Rosenthal R, et al. Improving the care of individuals with schizophrenia and substance use disorders: Consensus recommendations. J Psychiatric Practice. 2005;11:315-339. (Pubitemid 41540226)
148. Siris S, Mason S, Bermanzohn P, et al. Adjunctive imipramine in substance-abusing dysphonic schizophrenic patients. Psychopharmacol. 1993; 29:127-133. (Pubitemid 23204892)
149. Barrowclough C, Haddock G, Beardmore R, et al. Evaluating integrated MI and CBT for people with psychosis and substance misuse: Recruitment, retention and sample characteristics of the MIDAS trial. Addict Behav. 2009;34:859-866.
150. Cleary M, Hunt G, Matheson S, et al. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database of Systematic Rev. 2008;23:CD001088.
151. Drake R, Mueser K. Psychosocial approaches to dual diagnosis. Schizophrenia Bull. 2008;26:105-118.
152. Horsfall J, Cleary M, Hunt G, et al. Psychosocial treatments for people with co-occurring severe mental illnesses and substance use disorders (dual diagnosis): A review of empirical evidence. Harv Rev Psychiatry. 2009;17:24-34.
153. Tsuang J, Ho A, Eckman T, et al. Dual diagnosis treatment for patients with schizophrenia who are substance dependent. Psichiatr Serv. 1997;48: 887-889. (Pubitemid 27295208)
154. Bonsack C, Montagrin Y, Favrod J, et al. Motivational interviewing for cannabis users with psychotic disorders. Encephale. 2007;33:819-826. (Pubitemid 351621962)
155. Martino S, Carroll K, Nich C, et al. A randomized controlled pilot study of motivational interviewing for patients with psychotic and drug use disorders. Addiction. 2006;101:1479-1492. (Pubitemid 44337773)
156. Barrowclough C, Haddock G, Tarrier N, et al. Randomized controlled trial of motivational interviewing, cognitive behaviour therapy and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry. 2001;158:1706-1713. (Pubitemid 32923666)
157. Haddock G, Barrowclough C, Tarrier N, et al. Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse. 18-month outcomes of a randomised controlled trial. B J Psychiatry. 2003;183:418-426. (Pubitemid 37357574)
158. Barrowclough C, Haddock G, Wykes T, et al. Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: Randomised controlled trial. BMJ. 2010;341:c6325. Doi: 10.1136/ bmj.c6325.
159. Graeber D, Moyers T, Griffith G, et al. A pilot study comparing motivational interviewing and an educational intervention in patients with schizophrenia and alcohol use disorders. Community Ment Health J. 2003;39:189-202. (Pubitemid 38076681)
160. Kavanagh D, Young R, White A, et al. A brief motivational intervention for substance misuse in recent-onset psychosis. Drug Alcohol Rev. 2004; 23:151-155. (Pubitemid 38907018)
161. Shaner A, Roberts L, Eckman T, et al. Monetary reinforcement of abstinence from cocaine among mentally ill patients with cocaine dependence. Psychiatr Serv. 1997;48:807-810. (Pubitemid 27232880)
162. Roll J, Chermack S, Chudzynski J. Investigating the use of contingency management in the treatment of cocaine abuse among individuals with schizophrenia: A feasibility study. Psychiatry Res. 2004;125: 61-64. (Pubitemid 38210253)
163. Sigmon S, Higgins S. Voucher-based contingent reinforcement of marijuana abstinence among individuals with serious mental illness. J Subst Abuse Treat. 2006;30:291-295. (Pubitemid 43729154)
164. Kemp R, Harris A, Vurel E, et al. Stop using stuff: Trial of a drug and alcohol intervention for young people with comorbid mental illness and drug and alcohol problems. Australasian Psychiatr. 2007; 15:490-493. (Pubitemid 350120847)
165. Naeem F, Kingdon D, Turkington D. Cognitive behaviour therapy for schizophrenia in patients with mild to moderate substance misuse problems. Cogn Behav Ther. 2005;34:207-215. (Pubitemid 43123590)
166. Ho A, Tsuang J, Liberman R, et al. Achieving effective treatment of patients with chronic psychotic illness and comorbid substance dependence. Am J Psychiatry. 1999;156:1765-1770. (Pubitemid 29517570)
167. James W, Preston N, Koh G, et al. A group intervention which assists patients with dual diagnosis reduce their drug use: A randomized controlled trial. Psychol Med. 2004;34:983-990. (Pubitemid 39199968)
168. Tsuang J, Fong T. Treatment of patients with schizophrenia and substance abuse disorders. Curr Pharm Des. 2004;10:2249-2261. (Pubitemid 38832767)
169. Lybrand J, Caroff S. Management of schizophrenia with substance use disorders. Psychiatr Clin North Am. 2009;32:821-833.
170. Baker A, Hides L, Lubman D. Treatment of cannabis use among people with psychotic and depressive disorders: A systematic review. J Clin Psychiatr. 2010;71:247-254.
171. Timko C, Moos R. Symptom severity, amount of treatment, and 1-year outcomes among dual diagnosis patients. Adm Policy Ment Health. 2002;30: 35-54. (Pubitemid 36008052)
172. Green A, SalomonM, BrennerM, et al. Treatment of schizophrenia and comorbid substance use disorder. Curr Drug Targets CNS Neurol Disord. 2002;1:129-139.
173. Bellack A, Bennet M, Gearon J, et al. A randomized clinical trial of a new behavioural treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry. 2006;63:426-432.
174. Green A. Pharmacotherapy for schizophrenia and co-occurring use disorders. Neurotox Res. 2007;11: 33-40.
175. Ley A, Jeffery D, McLaren S, et al. Psychosocial treatment programs for people with both severe mental illness and substance misuse. Oxford (GB): The Cochrane Library; 2003.
176. Brunette M, Asher D, Whitley R, et al. Implementation of integrated dual disorders treatment: A qualitative analysis of facilitators and barriers. Psychiatr Serv. 2008;59:989-995.
177. Lehman A, Herron J, Schwartz R, et al. Rehabilitation for adults with severe mental illness and substance use disorders. J Nerv Ment Dis. 1993;181: 86-90. (Pubitemid 23090157)
178. Bachmann K, Moggi F, Hirsbrunner H, et al. An integrated treatment program for dually diagnosed patients. Psychiatr Serv. 1997;48:314-316. (Pubitemid 27113694)
179. Hanson M, Kramer T, Gross W. Outpatient treatment of adults with coexisting substance use and mental disorders. J Subst Abuse Treat. 1990;7: 109-116. (Pubitemid 20274433)
180. Mueser K, Drake R, Clark R, et al 1995;Tool kit on evaluation substance abuse in persons with severe mental illness. The Evaluation Center©HSRI.
181. Carey K. Emerging treatment guidelines for mentally ill chemical abusers. Hosp Commun Psychiatr. 1989;40:341-349.
182. Fernández Fernández J, Tourino González R. Evaluation and intervention of the dual disorder in psicosocial rehabilitation. Rehabilitación Psicosocial. 2006;3:9-16.
183. Drake R, Noordsy D. The role of inpatient care for patients with co-occurring severe mental disorder and substance use disorder. Community Ment Health J. 1995;31:279-282.
184. Strickler D, Whitley R, Becker D, et al. First person accounts of long-term employment activity among people with dual diagnosis. Psychiatr Rehabil J. 2009;32:261-268.
185. Hellerstein D, Rosenthal R, Miner C. A prospective study of integrated outpatient treatment for substance- abusing schizophrenic patients. Am J Addict. 1995;4:33-42.